An ongoing dialogue on HIV/AIDS, infectious diseases,
December 17th, 2015
A Certain Billionaire’s Arrest Prompts Universal Responses — and a Brilliantly Funny One, Too
Several words swiftly come to mind when hearing the news that Turing’s Martin Shkreli was arrested for security fraud. Karma. Just desserts. Kismet. Schadenfreude. Inevitable. But leave it to Andy Borowitz to get it just right: Ha, that’s perfect. Diana Olson from IDSA emailed me “Someone should make a movie …”, which is of course exactly right. What a script: […]
September 24th, 2015
Decision to Lower Price of Pyrimethamine a Good One, Especially Given the Weak Defense of the Price Hike
The big ID story the past couple of weeks is that the price of pyrimethamine — a drug that’s been available generically for decades — went from $13.50 to $750 for one pill after the exclusive rights to the drug were purchased by Turing Pharmaceuticals. Now, after a barrage of criticism — all the way from this […]
Paul E. Sax, MD
Contributing Editor
NEJM Journal Watch
Infectious Diseases
Biography | Disclosures | Summaries
Learn more about HIV and ID Observations.
NEJM Journal Watch — Recent Infectious Disease Articles- When it Comes to Antimicrobial Stewardship, Is a Boost Better Than a Nudge?
- HIV Prevention and Treatment: Updated Recommendations from the International AIDS Society–USA
- Observations from ID and Beyond: Dr. Thomas O'Brien — Expert in Antimicrobial Resistance and Giant in His Field (Literally)
- How Serious Is Artemisinin Partial Resistance in African Malaria Parasites?
- Observations from ID and Beyond: Who's Going to Get Lenacapavir for HIV Prevention?